Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis

AIMS: Intravenous ferric carboxymaltose (FCM) has been shown to improve functional capacity and quality of life in iron deficient heart failure patients. However, FCM's effect on hospitalizations and mortality remains unclear as previous randomized controlled trials (RCTs) and their meta‐analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Shahzeb, Usman, Muhammad Shariq, von Haehling, Stephan, Doehner, Wolfram, Stewart Coats, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754952/
https://www.ncbi.nlm.nih.gov/pubmed/33586856
http://dx.doi.org/10.1002/ehf2.13146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754952/
https://www.ncbi.nlm.nih.gov/pubmed/33586856
http://dx.doi.org/10.1002/ehf2.13146

Ejemplares similares